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Background: Mixed phenotype acute leukemias (MPAL) include acute leukemias with blasts that express antigens
of more than one lineage, with no clear evidence of myeloid or lymphoid lineage differentiation. T/myeloid (T/My)
MPAL not otherwise specified (NOS) is a rare leukemia that expresses both T and myeloid antigens, accounting
for less than 1% of all leukemias but 89% of T/My MPAL. From a molecular point of view, very limited data are
available on T/My MPAL NOS.
Case presentation: In this report we describe a T/My MPAL NOS case with a complex rearrangement involving
chromosomes 5 and 14, resulting in overexpression of the ADAM metallopeptidase with thrombospondin type 1
motif, 2 (ADAMTS2) gene due to its juxtaposition to the T cell receptor delta (TRD) gene segment.
Conclusion: Detailed molecular cytogenetic characterization of the complex rearrangement in the reported T/My
MPAL case allowed us to observe ADAMTS2 gene overexpression, identifying a molecular marker that may be useful
for monitoring minimal residual disease. To our knowledge, this is the first evidence of gene dysregulation due to a
chromosomal rearrangement in T/My MPAL NOS.
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Mixed phenotype acute leukemias (MPAL) include acute
leukemias with blasts that express antigens of more
than one lineage, with no clear evidence of myeloid
or lymphoid lineage differentiation [1]. Two provisional
MPAL entities are defined, with regard to the associ-
ation with the t(9;22)(q34;q11.2)/BCR-ABL1 and with the
t(v;11q23)/MLL rearrangements. The term T/myeloid
(T/My) and B/myeloid (B/My) MPAL not otherwise
specified (NOS) refers to leukemia cases with both T or
B and myeloid antigens, respectively, but without the
above-mentioned genetic abnormalities [1]. T/My MPAL
NOS is a rare leukemia accounting for less than 1% of all
leukemias but 89% of T/My MPAL [2]; it can be seen
in both children and adults and is generally considered
to have poor prognosis [1,2]. In a recent large series of* Correspondence: francesco.albano@uniba.it
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unless otherwise stated.patients affected by MPAL NOS, the most common
abnormalities observed were complex karyotypes with a
relatively frequent involvement of chromosomes 6q, 5
and 7 [2]. From a molecular point of view, data on T/My
MPAL NOS are very scanty and limited. The most fre-
quent cytogenetic abnormality in some T-cell disorders is
the presence of chromosomal translocations with break-
points in one of the T-cell receptor (TCR) loci [3]. As a
result of this kind of rearrangement, the expression of
the partner gene is dysregulated as the gene is placed
under the transcriptional control of the TCR locus [4]. In
this report we describe a T/My MPAL NOS case with a
complex rearrangement involving chromosomes 5 and
14, resulting in overexpression of the ADAM metallopep-
tidase with thrombospondin type 1 motif, 2 (ADAMTS2)
gene due to its juxtaposition to the T cell receptor delta
(TRD) gene segment. To our knowledge, this is the first
evidence of gene dysregulation due to a chromosomal
rearrangement in T/My MPAL NOS.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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A young man aged 18 years was referred to our center
for laterocervical lymphadenopathy and anemia. Periph-
eral blood smears analysis showed the presence of blast
cells (19%). Bone marrow aspirate and biopsy confirmed
diffuse blast infiltration (90%), characterized by a mixed-
cell population of large and small blasts (Figure 1A-C).
Immunophenotype analysis showed that blast cells were
HLA-DR+, CD4+ CD5+, CD7+, cyCD3+, CD13+, CD33+,
CD34+, MPO+, CD117+, CD56+. Conventional cytogen-
etic analysis of G-banded BM metaphase cells showed
the following karyotype: 46,XY,?t(5;14)(q11;q11),?inv(6)
(p11;p21)[9]/46,XY,idem,del(11q)[8]/46,XY[3]. Molecular
analysis showed the occurrence of the FLT3 internal
tandem mutation and the absence of the NPM1 mutation
and BCR-ABL1 fusion gene. A diagnosis of T/My MPAL
NOS was made according to the 2008 WHO criteria.
The patient was treated with chemotherapy according
to the Medical Research Council (UKALL XII)/ Eastern
Cooperative Oncology Group (E2993) chemotherapy regi-
men [5]. After induction treatment the patient obtained
complete hematological remission, which persisted during
the consolidation and maintenance therapy. At these time
points bone marrow immunophenotype analysis did not
show the presence of blast cells. After sixteen months
from the diagnosis, the patient is doing well and is still in
hematologic, cytogenetic and molecular remission, defined
by the ADAMTS2 gene expression analysis.
To confirm the conventional cytogenetic data regard-
ing the t(5;14)(q11;q11) rearrangement, reiterative Fluor-
escence in situ hybridization (FISH) experiments with
specific bacterial artificial chromosome (BAC) clones
were carried out. FISH analyses were performed on BM
samples, using BAC selected according to the UniversityFigure 1 May-Grunwald-Giemsa–stained bone marrow smear. (A) A m
of different sized blast cells.of California Santa Cruz database (UCSC http://genome.
ucsc.edu/; Feb. 2009 release). Chromosome preparations
were hybridized in situ with probes labeled by nick trans-
lation, as previously described [6]. FISH cohybridizations
were done by chromosome walking, employing a total of
10 and 8 selected clones belonging to chromosomes 5 and
14, respectively (Table 1). According to the FISH pattern,
a complex mechanism of double insertion with a concomi-
tant duplication of the chromosome 5q pericentromeric
region was hypothesized (Figure 2). In detail, chromosome
14 showed three different breakpoints: BAC clone RP11-
990 K12 (chr14:22,860,409-23,039,541) was the insertion
site of the chromosome 5 segment as it produced a signal
on normal chromosome 14 and a splitting signal on der
(14) (Figures 2 and 3A), whereas the region included
between BAC clones RP11-696 J16 (chr14:23687161–
23889944) and RP11-634B2 (chr14:99,566,527-99,778,328)
was inserted in chromosome 5, as both clones showed a
signal on normal chromosome 14 and a splitting signal on
der(14) and der(5) (Figure 2). As for the chromosome 5
breakpoints, the region included between BAC clones
RP11-641 M21 (chr5:178,525,062-178,697,496) (Figure 3A)
and RP11-1150B10 (chr5:49406372–49441108) was in-
serted on der(14) as both clones hybridized on chromo-
somes 5, der(5) and der(14). Moreover, a duplicated region
spanning from BAC RP11-1079 J18 (chr5:54403379–
54555179) up to the centromere was identified on der(5).
The insertion breakpoint of the chromosome 14 segment
into chromosome 5 was mapped next to the chromo-
some 5 telomeric region between BAC clones RP11-
834P23 (chr5:180585112–180782496) and RP11-242C5
(chr5:180720141–180862796) (Figure 2).
After the achievement of complete hematologic remis-
sion, FISH analysis no longer revealed the presence of theixed-cell population of large and small blasts is observed. (B-C) Detail
Table 1 BAC clones employed in FISH experiments
BAC clones Chromosomal band Genomic position FISH pattern
CHR 5 RP11-1149B6 5p11 chr5:46235286-46384443 5 + der(5)
RP11-1150B10 5q11.1 chr5:49,406,372-49,441,108 5 + der(14) + der(5)
RP11-1148I4 5q11.2 chr5:54,282,577-54,428,396 5 + der(14) + der(5)
RP11-1079 J18 5q11.2 chr5:54403379-54555179 5 + der(14) + der(5)
RP11-643H16 5q11.2 chr5:54612019-54764948 5 + der(14)
RP11-699D5 5q32 chr5:148,691,900-148,899,365 5 + der(14)
RP11-641 M21 5q35.3 chr5:178,525,062-178,697,496 5 + der(14) + der(5)
RP11-994H18 5q35.3 chr5:180,532,073-180,720,900 5 + der(5)
RP11-834P23 5q35.3 chr5:180,585,112-180,782,496 5 + der(5)
RP11-242C5 5q35.3 chr5:180,720,141-180,862,796 5 + der(5)
CHR 14 RP11-614 K19 14q11.2 chr14:22,656,994-22,845,933 14 + der(14)
RP11-990 K12 14q11.2 chr14:22,860,409-23,039,541 14 + der(14) splitting signal
RP11-1083 M21 14q11.2 chr14:23068756-23274125 14 + der(14)
RP11-909B16 14q11.2 chr14:23431729-23628645 14 + der(14)
RP11-696 J16 14q11.2 chr14:23687161-23889944 14 + der(14) + der(5)
RP11-828D3 14q11.2 chr14:23,897,700-24,068,595 14 + der(5)
RP11-634B2 14q32.2 chr14:99,566,527-99,778,328 14 + der(14) + der(5)
RP11-1145H5 14q32.33 chr14:106,995,083-107,135,809 14 + der(14)
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cluded the possibility of investigating the other chromo-
somal abnormalities pointed out by the karyotypic analysis.
According to the UCSC database, the ADAMTS2 and
TRD genes were mapped in correspondence with theFigure 2 Schematic representation of the complex chromosomes 5 an
juxtaposed next to the TRD locus on der(14) in this case of T/My MPAL.chromosomes 5 and 14 breakpoints, respectively. There-
fore, as a consequence of the complex chromosomal
rearrangement, the ADAMTS2 gene was juxtaposed to
the TRD locus on the der(14) chromosome. In particular,
the FISH pattern data suggested that the breakpointd 14 chromosomal rearrangement. The ADAMTS2 gene was
Figure 3 FISH analysis and breakpoints identification. (A) FISH cohybridization with BAC clones RP11-641 M21 (specific for the ADAMTS2 gene) and
RP11-990 K12 (specific for the TRD locus), identifying chromosomes 5 and 14 breakpoints, respectively. (B) The break in BAC RP11-641 M21 maps in the
region included between exon 3 and 4 of the ADAMTS2 gene (red arrow); exons 1–3 encode for the propeptide domain of the ADAMTS2 protein.
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exons 3 and 4 (Figure 3B). Bioinformatic analysis was
performed by querying the Conserved Domain Database
(http://www.ncbi.nlm.nih.gov/cdd ) for the annotation
of functional domain proteins encoded by the coding
sequence of the ADAMTS2 gene. This analysis clarified
that the exons 1–3, retained on der(5), code for the
N-terminal propeptide domain of the metallopeptidase
ADAMTS2; moreover, exons 4–22, transferred on der(14),
encode for catalytic, disintegrin-like, cysteine-rich, spacer, 4
thrombospondin and procollagen N propeptidase domains
(Figure 3B).
To verify the dysregulated expression of the ADAMTS2
gene portion juxtaposed to the TRD locus on der(14),
quantitative real-time PCR (qRT-PCR) analysis was carried
out on the sample at diagnosis. Total RNA derived from
BM cells was reverse transcribed into cDNA using the
QuantiTect reverse transcription kit (Qiagen, Chatsworth,
CA, USA). qRT-PCR experiments were carried out by
using the LightCycler 480 SYBR Green I Master mix on
the LightCycler 480II (Roche Diagnostics, Indianapolis,
IN, USA). All samples were run in triplicate as tech-
nical replicates. The β-glucuronidase (β-GUS) gene was
employed as endogenous control and a commercial pool
of cDNA derived from healthy individuals BM cells
(Clontech, US) was used as calibrator. Gene expression
level was also compared to two pools of three normal
karyotype (NK) AML and acute lymphoblastic leukemia
(ALL) cases, respectively. Bone marrow samples from
these patients were retrospectively obtained from the
hospital archive. For ADAMTS2 gene expression analysis,
primers specific for exons 6 and 7 were selected accord-
ing to the Primer3 software (http://frodo.wi.mit.edu)
(forward primer: GCCACGATGAATACCACGAT, re-
verse primer: GGTGACAGGAGCATAGCCTTG). qRT-
PCR experiments showed a higher expression level (61-fold
change) compared to that of healthy bone marrow,NK-AML, and NK-ALL pools. qRT-PCR analysis was later
performed at the time of complete hematologic and cyto-
genetic response and during the follow-up, revealing that
by that time the ADAMTS2 gene expression was not differ-
ent from that observed in control sample (Figure 4).
Discussion
The rarity of T/My MPAL NOS and the lack of applica-
tion, in the cases described in literature, of the diagnos-
tic criteria defined by the World Health Organization
(WHO) classification, have made it difficult to establish
whether this kind of leukemias has distinct biological
features. In MPAL NOS no single karyotypic aberration
was clearly recurrent, indicating that the leukemogenic
process does not result from a specific genetic abnor-
mality [2]. In this report we describe ADAMTS2 gene
overexpression following a complex rearrangement in-
volving chromosomes 5 and 14 in a T/My MPAL NOS
patient. This gene encodes a member of the ADAMTS
proteins, a family of 19 secreted enzymes which has a
role in extracellular matrix degradation and turn-over
and has previously been involved in several biological
processes such as cancer, coagulation, angiogenesis and
cell migration [7]. Mutations in the ADAMTS2 gene can
induce the Ehlers-Danlos syndrome type VIIC, a reces-
sive inherited connective-tissue disorder [8]. To date,
there are no data about the link between ADAMTS2
function and leukemogenesis. ADAMTS2 has been re-
ported to exert anti-angiogenic properties in vivo and
in vitro through nucleolin, a nuclear protein also found
to be associated with the cell membrane [9]. It is note-
worthy that a recent study demonstrated significantly el-
evated nucleolin levels in acute myeloid leukemia (AML)
patients, and that nucleolin overexpression was associ-
ated with DNA methyl transferase 1 upregulation and
shorter survival [10]. Our report does not include data
regarding nucleolin activity, but in the light of these data
Figure 4 qRT-PCR analysis. Graphic representation of ADAMTS2 gene relative expression evaluated in the T/My MPAL patient at onset, 2 and
16 months after the diagnosis (blue). The ADAMTS2 gene expression in the pool of NK-AML and NK-ALL cases is indicated in yellow and red,
respectively. Normal bone marrow (NBM) was employed as calibrator (green).
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sion may have a role in the leukemogenesis process.
Although ADAMTS2 has been reported as tumour sup-
pressor protein because of its anti-angiogenic properties
[9], it is possible that a different function is carried out
in hematopoietic tissue and that this function may be
impaired, in our case, by the chromosomal rearrange-
ment involving ADAMTS2. However, in our report no
experimental validation has been performed to verify the
leukemogenic potential of ADAMTS2 gene as a conse-
quence of the TCR locus juxtaposition and possibly con-
stitutively metalloprotease activation.
It is interesting to note that the ADAMTS2 protein is
physiologically synthesized as inactive zymogens, and its
N-terminal propeptide is cleaved by furin, a proprotein
convertase. This posttranslational modification is neces-
sary for its activation. In this respect, in our case the
ADAMTS2 gene exons 1–3 encoding for the propeptide
domain were retained on der(5) whereas the remaining
ADAMTS2 coding exons, that were found to be trans-
ferred adjacent to the TCRD locus on der(14), were
overexpressed. Therefore, it is plausible that a rearrange-
ment of the ADAMTS2 gene may be responsible for the
production of an already active protein.
In T-cell ALL, up to 22 different oncogenes have been
identified as TCR translocation partners; the LMO2,
TAL1, and TLX1 genes were most frequently involved in
these rearrangements and the majority of all TCR trans-
locations involved the TRD locus [3]. These aberrant
recombinations result in juxtaposition of oncogenes in
the vicinity of TCR cis-acting regulatory elements such
as enhancers, which promote their expression [11]. In
this respect our case showed three novel aspects: i) the
first one is the fact that the ADAMTS2 gene has never
been described as a partner of rearrangement of theTCR locus; ii) the rearrangement between ADAMTS2
and the TRD locus occurred through a mechanism of
chromosomal insertion instead of translocation; iii) a
dysregulated gene expression based on enhancer swap-
ping [12,13] has never been reported in T/My MPAL.
Data on the outcome of patients with MPAL are lim-
ited. Our patient was treated with the ALL-based regi-
men and achieved an optimal response. This observation
confirmed previous findings arguing that ALL-based
treatment seems more effective, with a higher response
rate and better outcome, as compared with an AML or
AML/ALL schedule [2,14]. Apart from patient age,
karyotypic and/or molecular associated aberrations may
have a relevance, from the prognostic point of view, in
T/My MPAL NOS.
Conclusions
Detailed molecular cytogenetic characterization of the
complex rearrangement in this T/My MPAL case allowed
us to observe ADAMTS2 gene overexpression, identifying
a molecular marker that may be useful for monitoring
minimal residual disease. In fact, the achievement of
hematologic and cytogenetic response was associated with
a normal ADAMTS2 gene expression, comparable to that
of healthy controls. In conclusion, considering the fact that
T/My MPAL NOS is a disease whose biology and progno-
sis has not been completely defined because of its rarity,
the possibility of carrying out molecular monitoring offers
a great advantage, in order to be able to plan therapeutic
treatments before it is possible to gain hematological or
clinical evidence of leukemia relapse.
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